Tidal Investments LLC Boosts Stock Holdings in Grifols, S.A. $GRFS

Tidal Investments LLC raised its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 9.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,233,082 shares of the biotechnology company’s stock after acquiring an additional 109,612 shares during the quarter. Tidal Investments LLC owned approximately 0.18% of Grifols worth $8,730,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Royal Bank of Canada increased its position in shares of Grifols by 21.7% during the first quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company’s stock worth $3,461,000 after purchasing an additional 86,768 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Grifols in the 1st quarter valued at $184,000. Goldman Sachs Group Inc. boosted its stake in Grifols by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after purchasing an additional 80,507 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after buying an additional 4,604 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in shares of Grifols by 11.6% during the second quarter. Sei Investments Co. now owns 2,081,535 shares of the biotechnology company’s stock worth $18,817,000 after buying an additional 216,793 shares in the last quarter.

Grifols Stock Down 1.3%

NASDAQ GRFS opened at $7.55 on Friday. The business’s fifty day simple moving average is $7.73 and its 200-day simple moving average is $7.89. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The firm has a market cap of $5.14 billion, a PE ratio of 39.74, a P/E/G ratio of 0.28 and a beta of 0.67. Grifols, S.A. has a 52 week low of $6.96 and a 52 week high of $10.23.

Grifols Announces Dividend

The business also recently announced a special dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.0945 per share. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s dividend payout ratio (DPR) is 42.11%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $10.00.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases.

Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases.